Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)
NHS England · Awarded
- Buyer
- NHS England
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Professional Services
- Reference
- FaT-ocds-h6vhtk-0595dd
- Published
- 2026-01-16
- Deadline
- 2026-04-10
Tender summary
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients…
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access